Phase 1 N=39 IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=208 MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
Advanced Malignant Solid Neoplasm
Primary: Number of Participants With an Objective Response — 0; 0; 0; 0 Participants
Phase 1 N=18 HCW9218 in Select Advanced Solid Tumors
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 1 N=61 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Phase 1 N=21 Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors
Cancer
Primary: Response and Progression Will be Evaluated in This Study Using the New International Criteria Proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)…
Phase 2 N=345 Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Advanced Solid Tumors
Primary: Overall Response Rate (ORR) — 5.6; 0.0; 11.3; 14.3 percentage of participants
Phase 2 N=50 Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity — 11 Participants
Phase 1 N=62 Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Advanced Solid Tumor
Primary: Number of Participants Experienced Dose Limit Toxicities (DLT) — 0; 0 Participants
Phase 2 N=12 Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Solid Malignancy · Solid Tumor
Primary: Response Rate (RR) — 1 Participants
Phase 2 N=29 M6620 (VX-970) in Selected Solid Tumors
Solid Tumor · Leiomyosarcoma · Osteosarcoma
Primary: Changes in Phospho-Chk1 Levels in Biopsy Specimens — 156; 196; 89; 84 percent change
Phase 2 N=252 A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
Advanced Unresectable or Metastatic Solid Malignancy
Primary: Confirmed Objective Response Rate (ORR) Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Response…
Phase 2 N=37 Cabozantinib in Advanced Solid Malignancies
Lung Cancer · Solid Tumor (Not Breast or Prostate Cancers)
Primary: Number of Participants With Bone Bio-marker Response — 13; 9; 8 Participants
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 1 N=43 A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors
Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 4; 3; 13; 3 Participants
Phase 1 N=34 AZD1775 for Advanced Solid Tumors
Solid Tumors
Primary: To Establish the Safety and Tolerability of Single-agent AZD1775 in Patients With Refractory Solid Tumors — 6; 4; 6; 3 Participants
Phase 1 N=32 Pazopanib and ARQ 197 for Advanced Solid Tumors
Solid Tumor
Primary: Number of Grade 3 or 4 Adverse Events, Highest Occurrence Per Participant — 1; 0; 0; 0 Adverse events
Phase 1 N=120 Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Endometrial Adenocarcinomas · Neuroendocrine Tumors · Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
Primary: Maximum Tolerated Dose (MTD) — 50; 50; 5.0; 5.0 DOX mg/m2 PM01183 mg FD
Phase 1 N=26 A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Phase 1 N=116 A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Advanced Solid Tumors · Advanced Recurrent Ovarian Tumors
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 1; 1; 2; 1 Participants
Phase 1 N=32 Study of E7389 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Determination of the Maximum Tolerated Dose — 1.0 mg/m^2
Phase 2 N=57 Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies
Oncology · MET Gene Amplification · NSCLC
Primary: Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration — 0; 0; 0; 0 Number of DLTs
Phase 1 N=98 Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Neoplasms
Primary: Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy — 5; 5; 5; 5 mg BID
Phase 2 N=35 TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
Lymphomas · Solid Tumors · NSCLC
Primary: Phase 2: Response Rate of This Combination in Participants With Colon Cancer, Non-small Cell Lung Cancer (NSCLC), and Granulosa Cell Ovarian Cancer — 0; 0; 0; 1…
Phase 1 N=15 Study of IMC-1121B in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Number of Participants With Drug-Related Adverse Events — 3; 6; 6; 0 participants
Phase 2 N=4 M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
Colon Adenocarcinoma · High-Frequency Microsatellite Instability · Metastatic Malignant Solid Neoplasm
Primary: Percentage of Circulating DNA Clearance — 0 percentage of DNA cleared
N/A N=2,165 Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
Phase 2 N=100 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
Non-small Cell Lung Carcinoma · Urothelial Carcinoma · Gastrointestinal Carcinoma, Non-colon
Primary: Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations — 10.3; 0; 7.1; 0 percentage of participants
Phase 2 N=140 Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Advanced Rare Tumours
Primary: Objective Response Rate Measured by RECIST Version 1.1 — 1; 19; 32; 76 Participants
Phase 1 N=11 Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) — 0; 3 Number of participants